A5000379018- Cardiac, Anesthesia and Surgical Outcomes
- Glaucoma and retinal disorders
- Enhanced Recovery After Surgery
- Ocular Surface and Contact Lens
- RNA regulation and disease
- Retinal Diseases and Treatments
- Hip and Femur Fractures
- Retinal Imaging and Analysis
- Anatomy and Medical Technology
- Colorectal Cancer Surgical Treatments
- Ocular Diseases and Behçet’s Syndrome
- Retinal Development and Disorders
- Renal cell carcinoma treatment
- Advances in Oncology and Radiotherapy
- Renal and related cancers
- Inflammatory mediators and NSAID effects
- Health Sciences Research and Education
- Retinal and Macular Surgery
- Horticultural and Viticultural Research
- Reconstructive Surgery and Microvascular Techniques
- Plant Reproductive Biology
- Appendicitis Diagnosis and Management
- Intraocular Surgery and Lenses
- Facial Rejuvenation and Surgery Techniques
- Advanced biosensing and bioanalysis techniques
University Hospitals Sussex NHS Foundation Trust
2023
King's College London
2021
University of Oxford
2017-2020
John Radcliffe Hospital
2018-2020
Churchill Hospital
2016-2018
London North West Healthcare NHS Trust
2018
Science Oxford
2017
Introduction: Age related macular degeneration (AMD) affects over 14 million people worldwide and is the commonest cause of visual loss in 65's age group industrialised world. The neovascular form AMD (nAMD) responsible for majority severe loss. introduction anti-vascular endothelial growth factor (anti-VEGF) agents mid 2000's revolutionised treatment nAMD. Of current three anti-VEGF widely used, Aflibercept (EYLEA®; Regeneron Pharmaceutical Inc., Tarrytown, NY, USA/Bayer Healthcare, Berlin,...